Predicting Progression to GA Using Imaging Biomarkers

Several OCT findings can help clinicians better understand a patient’s risk of progression to sight-threatening disease.

Kelly Donovan, MD, PhD, and Eleonora M. Lad, MD, PhD

Anti-VEGF Step Therapy: An Update

Despite ongoing advocacy efforts, this payer policy persists, putting vision at risk.

Lucas McGuire, BS; Baseer Ahmad, MD; and Jennifer Adeghate, MD, PhD

Novel MOAs in Wet AMD

The pipeline is full of therapies that hold promise for extending treatment efficacy.

Lejla Vajzovic, MD, FASRS; Robert L. Avery, MD; Carl D. Regillo, MD; and Durga S. Borkar, MD, MMCi

Pearls and Pitfalls of Treating GA and Wet AMD

Concurrent therapy can pose clinical challenges. Here’s how you can manage these patients and maximize outcomes.

Sean D. Adrean, MD, FAAO, and Wesley Han, BS